Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T-Cell Lymphoma
Version of Record online: 27 JAN 2014
Copyright © 2014 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 28, Issue 2, pages 529–537, March/April 2014
How to Cite
Warry, E.E., Willcox, J.L. and Suter, S.E. (2014), Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T-Cell Lymphoma. Journal of Veterinary Internal Medicine, 28: 529–537. doi: 10.1111/jvim.12302
- Issue online: 15 MAR 2014
- Version of Record online: 27 JAN 2014
- Manuscript Accepted: 11 DEC 2013
- Manuscript Revised: 24 OCT 2013
- Manuscript Received: 20 JUN 2013
- Bone marrow transplantation;
- Total body irradiation
Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B-cell lymphoma.
To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL).
Fifteen client-owned dogs diagnosed with high-grade TCL.
After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment.
More than 2 × 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post-PBHCT.
Conclusions and Clinical Importance
PBHCT may be considered as a treatment option for dogs with TCL.